Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J988- Other specified respiratory disorders
Conditions
Interventions
Intervention1: Betadine gargle and Nasal drops: Patients meeting inclusion and exclusion criteria will be identified and an informed, written consent will be obtained. The patients will randomly be al
Sponsors
DR S P AMBESH
Eligibility
Inclusion criteria
Inclusion criteria: COVID 19 positive by RT PCR analysis of nasopharyngeal/oropharyngeal specimens Patients admitted with mild COVID 19 infection with or without co morbidities.
Exclusion criteria
Exclusion criteria: Patients with tachypnoea Patients with SpO2less than 94% on room air Patients requiring oxygen supplementation or assisted ventilation at admission. Patients receiving antiviral agents Patients with known sensitivity to PVP-I. Pregnant patients and patients with thyroid diseases. Patients who refuse or are incapable of giving consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)To evaluate the efficacy of intranasal povidone iodine 1% solution and gargles in reducing the viral load of SARS CoV2 in nasopharynx of patients admitted with mild COVID 19 disease. 2)To evaluate clinical course in patients with mild COVID 19 illness who were treated with PVP-I gargle and intranasal solution with respect to ,Progression of disease Radiological features Inflammatory markers Timepoint: At baseline,at 1 week | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)To assess tolerability of PVP-I as gargle and intranasal solution in COVID 19 patients. 2)To study if intranasal Povidone Iodine 1% and gargles administration can reduce the duration of hospital stay among patients admitted with mild COVID 19 disease. Timepoint: 1 week | — |
Countries
India
Contacts
Public ContactDR ANUSREE EV
SGPGIMS,LUCKNOW
Outcome results
None listed